What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory…
What is Nektar Therapeutics's P/E and P/B ratio?
Nektar Therapeutics has a P/E ratio of -2.0 and a P/B ratio of 1.46.
What is Nektar Therapeutics's debt-to-equity ratio?
Nektar Therapeutics has a debt-to-equity ratio of 0.15.
How much does Nektar Therapeutics owe compared with what it owns?
Nektar Therapeutics owes $0.18 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Nektar Therapeutics's Positivity rank?
Nektar Therapeutics is ranked #2,582 of 6,774 companies globally and #867 of 4,000 in United States on PositoAI, with a Positivity Score of 21,359.
Does Nektar Therapeutics have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Nektar Therapeutics.
Where can I read the latest news about Nektar Therapeutics?
Recent headlines about Nektar Therapeutics from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Nektar Therapeutics have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Nektar Therapeutics's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.